Kai Riecke

Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans

Lucas T. van Eijk, Aaron S. E. John, Frank Schwoebel et al. · Blood · 2014 · 109 citations · Full text

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

Michael Steurer, Marco Montillo, Lydia Scarfò et al. · Haematologica · 2019 · 85 citations · Full text

Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects

Malcolm Boyce, Steve Warrington, B Cortezi et al. · British Journal of Pharmacology · 2016 · 79 citations · Full text

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Heinz Ludwig, Katja Weisel, Maria Teresa Petrucci et al. · Leukemia · 2017 · 79 citations · Full text

Myeloma Growth, Immunology, Phase Iia Study +20

An European inter-laboratory validation of alternative endpoints of the murine local lymph node assay

G. Ehling, Monica Hecht, A. Heusener et al. · Toxicology · 2005 · 65 citations

Lymphoid Neoplasia, Immunocytochemical Technique, Medicine +12